⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NRIX News
Nurix Therapeutics, Inc. Common stock
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
globenewswire.com
NRIX
Form 8-K
sec.gov
NRIX
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
NRIX
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
prnewswire.com
GTBP
XNCR
CTMX
ZYME
NRIX
Form 8-K
sec.gov
NRIX
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
globenewswire.com
NRIX
Form 8-K
sec.gov
NRIX
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
globenewswire.com
NRIX
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
globenewswire.com
NRIX
Form 8-K
sec.gov
NRIX